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Multiplication rate variation 
in the human malaria parasite 
Plasmodium falciparum
Lee Murray1, Lindsay B. Stewart1, Sarah J. Tarr1, Ambroise D. Ahouidi2,  
Mahamadou Diakite  3, Alfred Amambua-Ngwa4 & David J. Conway  1
It is important to understand intrinsic variation in asexual blood stage multiplication rates of the most 
virulent human malaria parasite, Plasmodium falciparum. Here, multiplication rates of long-term 
laboratory adapted parasite clones and new clinical isolates were measured, using a newly standardised 
assay of growth from low starting density in replicate parallel cultures with erythrocytes from multiple 
different donors, across multiple cycles. Multiplication rates of long-term established clones were 
between 7.6 and 10.5 fold per 48 hours, with clone Dd2 having a higher rate than others (clones 3D7, 
HB3 and D10). Parasite clone-specific growth was then analysed in co-culture assays with all possible 
heterologous pairwise combinations. This showed that co-culture of different parasites did not affect 
their replication rates, indicating that there were no suppressive interactions operating between 
parasites. Multiplication rates of eleven new clinical isolates were measured after a few weeks of 
culture, and showed a spectrum of replication rates between 2.3 and 6.0 fold per 48 hours, the entire 
range being lower than for the long-term laboratory adapted clones. Multiplication rate estimates 
remained stable over time for several isolates tested repeatedly up to three months after culture 
initiation, indicating considerable persistence of this important trait variation.
The malaria parasite Plasmodium falciparum is responsible for up to half a million human deaths each year1, but 
there are basic features of its biology that remain poorly understood. As the density of parasites is a primary deter-
minant of disease, identifying if there is intrinsic variation in parasite multiplication rates in the blood is impor-
tant from a clinical as well as evolutionary perspective2. Although very high parasite densities are associated 
with severe disease3, a larger number of infections are clinically mild, and sensitive detection methods reveal 
most infections to be asymptomatic with very low parasite densities4. Analyses of in vivo growth rate of P. falci-
parum, using historical data from induced-malaria treatments of neurosyphillis cases, indicated some variation 
in multiplication rates among three parasite strains, with an overall average estimate of approximately 8 fold per 
48 hour period5, although under alternative modelling parameters this could be slightly higher6. Recent studies of 
controlled human infections with P. falciparum clone 3D7 used in vaccine challenge studies also indicate a similar 
multiplication rate7. Although virulence may not be experimentally analysed in human infections, studies using 
rodent malaria parasites indicate that strain-dependent variation in parasite multiplication rate is associated with 
disease in mice2, 8.
Separate studies of P. falciparum clinical samples cultured through the first cycle ex vivo have indicated vari-
ation in multiplication rates, although these are generally lower than expected on the basis of the in vivo studies. 
Median multiplication rates of parasites from uncomplicated clinical malaria cases are reported as being 2.9-fold 
in a study in Thailand, 3.1-fold in Mali, 2.3-fold in Kenya, and approximately 3.3-fold in Uganda9–11. Parasites 
from severe malaria cases in Mali and Kenya had similar multiplication rates as those from uncomplicated cases10, 
whereas parasites from severe malaria cases in Thailand and Uganda were reported to have higher multiplication 
rates on average9, 11. A limitation of these studies is that they were based on only a single measurement per isolate, 
so they lack technical or biological replication. Additionally, assessment of parasite multiplication phenotypes 
in the first cycle ex vivo may be confounded by heterogeneous parasite viability or erythrocyte condition among 
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individual patients at the time of sampling, due to variable processing and storage of samples, or to physiological 
states including anaemia12.
Parasite multiplication rates have been assessed for only a few laboratory adapted clones of P. falciparum13, 
and from genetic cross progeny of two clones14, but these may not be representative of natural parasite popu-
lations. Many parasites that have been in culture for a long time are loss-of-function mutants, with particular 
genes having acquired premature stop codons15, or having been lost in subtelomeric deletions16. Determining the 
true range of variation in asexual multiplication rate of P. falciparum would be an important step in being able 
to identify determinants of growth and virulence factors. A feature of malaria infections in endemic regions is 
the presence of multiple distinct parasite clones within a proportion of individual hosts17, 18. Studies on rodent 
malaria models have given contrasting conclusions as to whether competitive suppression occurs between dif-
ferent co-infecting genotypes19, 20, and co-culture studies on P. falciparum have not yielded consistent findings on 
interactions between different clones21–23. It remains unknown how malaria parasites would be able to detect the 
presence of other clones within a multi-clone infection, or within heterologous co-cultures, although potential 
intercellular communication mechanisms are suggested24, 25.
A reliable assay is here described for quantifying P. falciparum asexual blood stage multiplication rates in a 
standardised manner over multiple cycles, using biological triplicate measurements in different erythrocytes. This 
is applied to measure the multiplication rate variation among unrelated laboratory clones cultured separately, and 
in mixed co-cultured combinations, as well as the multiplication rates of a panel of clinical isolates from three 
endemic countries.
Results
Quantifying multiplication rates of P. falciparum laboratory clones. Multiplication rates of four 
unrelated laboratory clones (Dd2, D10, HB3 and 3D7-HT-GFP) were measured, by analysing a six-day period 
of exponential growth from a starting inoculum density of 0.02% infected erythrocytes. Assays were conducted 
on each clone in parallel using six biological replications, with different donor erythrocytes in separate flasks. 
Parasite density in each flask on days 0, 2, 4 and 6 was quantified by qPCR measurement of parasite genome num-
bers per microlitre in sampled aliquots, and plotted on a log10 scale (Fig. 1A). This showed strong correlation with 
parasite numbers estimated by microscopy count data (Pearson’s r = 0.93, p-value < 1 × 10−10; Supplementary 
Fig. S1A), with marginally higher sensitivity achieved by qPCR (Supplementary Fig. S1B) as seen in a previous 
comparison26. Generalized linear modelling, with high coefficients of determination across all the biological rep-
licates for each clone (r2 > 0.95), yielded estimated multiplication rates per 48 hour period over the 6 day assay 
(Fig. 1B). Clone Dd2 had a higher multiplication rate (10.53 fold, 95% CI 6.79–13.07) than HB3 (7.59 fold, 95% 
CI 6.40–9.00), D10 (7.83 fold, 95% CI 6.52–9.41) and 3D7-HT-GFP (8.09 fold, 95% CI 6.79–9.64).
Figure 1. Measurement of exponential multiplication rates of laboratory adapted clones of P. falciparum. 
(A) 6-day growth assays for four laboratory clones, showing parasite density as numbers of genome copies 
per microlitre (on a log10 scale). Six biological replicates were performed using different donor erythrocytes. 
Estimation of parasite copy numbers by quantitative PCR was confirmed to be highly correlated with counts of 
parasites by microscopy of Giemsa-stained slides (Supplementary Figure S1). ‘3D7’ here refers to the genetically 
modified clone 3D7-HT-GFP35 whereas the other clones were not genetically modified. (B) General linear 
model estimates of the replication rates per 48 hours over the 6-day assays for each of the four laboratory clones 
(point estimates with 95% confidence intervals).
www.nature.com/scientificreports/
3ScienTific RepoRTS | 7:  6436 | DOI:10.1038/s41598-017-06295-9
Clone-specific multiplication rates in heterologous P. falciparum co-cultures. To test for potential 
interactions between different P. falciparum clones during co-culture, assays were performed for all six pair-
wise combinations of the four laboratory clones. Each of three allele-specific PCR assays required for measuring 
clone-specific growth in the co-cultures was first carefully validated. The proportions of genome copies measured 
for each parasite clone was highly concordant with the known proportions throughout the range of heterologous 
DNA mixed ratios from 1:99 o 99:1 (r2 values > 0.99 for each pairwise combination, Fig. 2A and Supplementary 
Fig. S2). To confirm that clone-specific proportions were faithfully measured from DNA extracted, a spectrum 
of ratios from 1:20 to 20:1 of two fluorescent parasite clones (Dd2-GFP and D10-mKate2) were measured using 
the quantitative allele-specific PCR assays and compared to direct live imaging fluorescent microscopy counting, 
confirming a high level of concordance between the methods (r2 values > 0.98, Fig. 2B).
All possible heterologous co-culture pairwise combinations at 1:1 ratios (each clone at a starting density of 
0.01% infected erythrocytes) were tested for multiplication rates in triplicate flasks with different donor erythro-
cytes. Allele-specific measurement of parasite genome copy numbers was performed on samples from the cultures 
at days 0, 2, 4 and 6, and multiplication rates per 48 hours derived by generalized linear modelling (Fig. 2C). For 
each of the clones, this allele-specific analysis of P. falciparum multiplication rates for the monoculture controls 
yielded similar estimates to those obtained in the independent experiments reported above using qPCR assays 
based on conserved sequences. Under all conditions, clone Dd2 had a higher multiplication rate than any of the 
other three clones. In comparison with monoculture controls, there was no reduction in multiplication rates seen 
in any parasite clone in any of the co-culture mixtures (Fig. 2C and Supplementary Table S1), indicating that there 
was no suppression due to heterologous interactions.
Figure 2. Quantitation of parasite multiplication rates for four laboratory clones across three intraerythrocytic 
cycles for all pairwise co-cultured combinations. (A) Allele-specificity of qPCR assays for clone-specific 
parasite density measurement. Three different allele-specific sets of assays were used to analyse all pairwise 
combinations of four P. falciparum laboratory clones. Each assay was first evaluated in a comparison of observed 
versus expected ratios for a pair of heterologous clones. The assay shown here is described in this paper, and 
discriminates msp6 alleles to accurately quantify Dd2 and D10 DNA mixed at different ratios from 1:99 to 99:1. 
Two different assays to discriminate msp1 alleles, used to quantify parasite DNA in other heterologous mixtures 
(Supplementary Figure S2), have been previously described21, 22. (B) Comparison of ratios of different parasite 
clones in mixtures assayed by fluorescence microscopy and allele-specific qPCR. There is a high correlation 
between the independent measurements (r2 = 0.984) across a range of ratios from 1:20 to 20:1 for the Dd2-
GFP and D10-mKate2 clonal mixtures. (C) P. falciparum clone-specific parasite multiplication rates (with 95% 
confidence intervals) are similar in monoculture and pairwise co-cultured combinations. ‘3D7′ here refers to 
the genetically modified clone 3D7-HT-GFP35. The allele-specific qPCR assays of parasite densities (at days 0, 2, 
4 and 6) yield estimates of clone-specific growth per 48 hour period by general linear modelling of exponential 
growth over six days (values are listed in Supplementary Table S1).
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Multiplication rates of P. falciparum clinical isolates. Multiplication rate assays were performed on 
eleven new P. falciparum clinical isolates, following at least two weeks of culture after isolation so that parasites 
were growing in erythrocytes from anonymous heterologous donors. Microsatellite genotype profiling of four 
loci confirmed that all isolates were genotypically distinct except for two of the Senegalese isolates (SEN215 
and SEN232, cultured at separate times, Supplementary Table S2). Three isolates (GUI246, MAL250, and 
SEN251) clearly contained multiple genotypes while each of the others contained a single predominant geno-
type (Supplementary Table S2). Parasite multiplication was determined from a starting density of 0.02% infected 
erythrocytes, after diluting into triplicate flasks with different donor erythrocytes under the same protocol as used 
for laboratory adapted clones. Analysis of parasite densities over a six-day period yielded lower coefficients of 
determination for multiplication rates of these clinical isolates (mean r2 = 0.89, range from 0.76 to 0.99) than had 
been seen with assays of the laboratory adapted clones reported above, and inspection of the data showed this was 
due to a lower multiplication rate after day 4 of the assay in several of the isolates (Supplementary Fig. S3). As the 
coefficient of determination values for the first 4 days of the assay were significantly higher (mean r2 = 0.94, range 
from 0.88 to 0.99), these data were used to estimate the multiplication rates per 48 hours.
The multiplication rates of the clinical isolates ranged from 2.26 to 6.00-fold, with a mean of 3.92-fold 
(Fig. 3A). In contrast, parasite clone 3D7-HT-GFP which was tested in parallel on all occasions had a consistently 
higher multiplication rate close to 8.0-fold, similar to that seen in all previous assays. Variation in multiplication 
rates of clinical isolates did not depend on whether they had single or multiple detected genotypes (means of 3.94 
and 3.86 fold respectively; Mann-Whitney test, P = 0.92). The multiplication rate variation also did not associate 
with use of alternative media supplements (mean of 3.71 fold for isolates grown with Albumax supplementation, 
and mean of 4.17 fold for isolates grown with Albumax and serum; Mann-Whitney test, P = 0.90).
As all eleven clinical isolates had lower multiplication rates than all four laboratory clones tested (Mann 
Whitney test, P < 0.001), it was considered that faster multiplication may be a trait selected during the process 
of culture adaptation. Although the length of time in culture of the eleven isolates prior to initial assay (between 
16 and 37 days) was not correlated with multiplication rate (Spearman’s ρ = 0.03, P = 0.92), to test for changes 
over a longer period four of the isolates were cultured for up to a few months and assayed at two additional time 
points. No significant changes in multiplication rate were detected over the periods investigated (Fig. 3B). The 
four isolates had a mean 48 hour multiplication rate of 5.11-fold at the first time point (16 or 18 days after culture 
initiation) and 5.25-fold at the last time point (76 or 100 days after culture initiation).
Discussion
Substantial intrinsic variation in P. falciparum multiplication rates is revealed, with long-term laboratory adapted 
lines multiplying between 7.6 and 10.5 fold every 48 hours and clinical isolates that have been cultured for only 
a few weeks multiplying between 2.3 and 6.0 fold every 48 hours. Previously reported multiplication rates for 
clinical malaria isolates involved single ex vivo assay measurements during the first cycle ex vivo9–11, and yielded 
slightly lower average multiplication rate estimates compared with those measured for the clinical isolates here. 
Figure 3. Parasite multiplication rates (with 95% confidence intervals) of new P. falciparum clinical isolates, 
sampled from patients in three West African countries (GUI, Guinea; SEN, Senegal, MAL, Mali). (A) Eleven 
isolates were analysed after growth in culture for at least two weeks (between 16 and 32 days) prior to assay. 
Exponential growth was measured over 4 days using a general linear model approach. All assays were 
conducted with biological triplicates in separate flasks with different donor erythrocytes, except for SEN232 
which was assayed in duplicate. Six of the isolates (SEN232, GUI246, MAL247, GUI249, MAL250, SEN251) 
were assayed in medium supplemented by Albumax and serum, whereas the other five were assayed by medium 
with Albumax alone as noted in the Materials and Methods (results were similar for the two groups, Mann-
Whitney test P = 0.90). As a control, the laboratory adapted clone 3D7-HT-GFP (here labelled ‘3D7′) was 
tested in parallel in each assay, yielding a consistent multiplication rate of approximately 8 fold per 48 hours. (B) 
Four of the clinical isolates cultured for longer periods were assayed at three different time points after culture 
initiation (up to 76 or 100 days for each isolate). These showed no significant changes in multiplication rate over 
time in culture. Assays were conducted with biological triplicates, except for the last cultured time point for 
which the assay was conducted in duplicate.
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Lack of biological replicates and variable viability of parasites in initial clinical samples are concerns for first cycle 
assays,, whereas the assays described here involved quantitation over multiple cycles and assay replicates using 
unrelated donor erythrocytes, to enable more robust comparisons of parasite multiplication rate phenotypes.
There were no significant short-term modifications in the multiplication rate of any parasite clone caused by 
co-culture with heterologous clones, under the assay conditions allowing exponential growth from a low starting 
density. Although inter-clonal suppressive effects might occur at higher densities in culture, previous attempts to 
investigate this have yielded variable results. One study suggested competitive suppression of clone HB3 by clone 
Dd2, based on endpoint density measurements after a short period of co-culture21, while another showed Dd2 
to have a more consistent average growth rate only slightly higher than that of HB3 in longer-term co-culture23. 
Another study indicated the general difficulty in separating any genotype-specific effects from those determined 
by total parasite density22. A recent study comparing two different clones has indicated differences in their density 
dependence when cultured separately27, a heterogeneity which would complicate the interpretation of co-culture 
at high densities.
Several different components of the parasite developmental cycle may potentially influence multiplication 
rates, including intraerythrocytic cycle duration, numbers of merozoites per schizont, and erythrocyte inva-
sion efficiency9, 28. A previous comparison of laboratory clones Dd2 and HB3 estimated that Dd2 had a shorter 
mean cycle time, a higher mean number of merozoites per schizont, and higher merozoite invasion efficiency13. 
Therefore, each of the measured parameters could contribute to the higher replication rate for Dd2 compared 
to HB3 that has been confirmed here. The potential contribution of these different parameters has yet to be 
determined for other laboratory clones or clinical isolates. The possible effects of host erythrocyte variation have 
been minimised in the current study by assaying each of the parasite lines in erythrocytes from multiple different 
anonymous donors as biological replicates. As erythrocyte variation can potentially affect parasite multiplication, 
it would be particularly interesting to test the relative multiplication rates of different parasite isolates in eryth-
rocyte types associated with protection from severe malaria in African populations, including locally selected 
glycophorin and haemoglobin variants29, 30.
Although multiplication rates were measured at multiple time points for several of the clinical isolates that 
were continued in culture for a few months, no significant changes were seen. It is likely that culture adaptation 
occurs over longer time scales, requiring sufficient numbers of generations to allow emerging adaptive mutants 
to go to high frequencies15. It may be expected that epigenetic regulation of clonally variable transcriptional vari-
ation could allow phenotypic change to occur more rapidly31, but expression profiles have not been characterised 
in clinical isolates during the process of culture adaptation, aside from analyses of candidate genes such as the 
highly transcriptionally variable var genes32 and merozoite invasion ligand genes33 in a small number of isolates.
Multiplication rate measurements are more robust when conducted over more than a single cycle, thereby 
requiring a minimum of four days to cover at least two of the 48 hour periods corresponding to an average rep-
lication cycle of this parasite species. Although laboratory adapted parasite clones showed consistent multipli-
cation rates throughout a six day growth assay, whether in monoculture or in mixed heterologous co-cultures, 
the clinical isolates showed more consistent growth during the first four days. As several of the clinical isolates 
showed slower growth later in the assay, which would have artificially lowered the multiplication rate estimates, 
analysis of multiplication over four days was more accurate, with higher coefficient of determination. Although 
data with lower measurement coefficients have previously been included for logistic multiplication rate estima-
tion in induced infections34, and culture assays23, a high threshold for inclusion such as applied here enables focus 
of analysis on more precise data. Study of heterogeneous samples can thereby be prospectively conducted with 
similarly tight assay replication, which would enable future comparisons of parasites from very low parasitaemia 
asymptomatic infections, or from high parasitaemia severe infections.
Materials and Methods
P. falciparum laboratory adapted clones and new clinical isolates. For monoculture and compet-
itive growth studies, four different P. falciparum laboratory adapted clones were studied that had been origi-
nally derived from clinical infections many years ago: Dd2 (from the area of Southeast Asia formerly known as 
‘Indochina’), HB3 (from Honduras), D10 (from Papua New Guinea), and 3D7 (from a case of ‘airport malaria’ 
in the Netherlands with a parasite type having genetic similarities to African P. falciparum isolates). For 3D7, a 
genetically modified sub-clone was used that had been previously engineered to express the green fluorescent 
protein (3D7-HT-GFP kindly provided by Professor Bob Sinden)35. This clone was used throughout as a control 
in the multiplication rate assays. These four laboratory-adapted lines were each cultured from pre-existing stocks 
and were not re-cloned prior to this study.
P. falciparum clinical isolates were sampled from patients who tested positive for malaria by immunochro-
matic rapid diagnostic testing and who had reported not taking antimalarial drugs during the preceding 3 days. 
Patients presented at local health facilities at three different sites in West Africa (Faranah in the Republic of 
Guinea in 2012, the Pikine area of Dakar in Senegal in 2013, and Nioro du Sahel in Mali in 2014), and written 
informed consent for blood sampling for the study was obtained from patients or their parents or guardians. 
Prior to antimalarial treatment, venous blood samples of up to 5 ml in volume were collected into anticoagulant 
tubes and centrifuged, following which plasma and leukocyte buffy coats were removed, and erythrocytes were 
cryopreserved in glycerolyte at −80 °C or in liquid nitrogen until shipment on dry ice to the London School of 
Hygiene and Tropical Medicine where culture was performed. Eighteen isolates (five from Guinea, nine from 
Senegal, and four from Mali) were selected for testing in this study after they had been cultured for at least two 
weeks, by which time the majority of erythrocytes had been replaced by those from non-patient donors. Isolates 
were given laboratory codes within a single series, so that laboratory workers were blinded to the origin of each 
isolate and the assays were conducted on parasites from different populations over the same period, as generally 
recommended for assays of clinical isolate phenotypes36. High quality assay data with sufficient biological and 
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technical replication were achieved for eleven of the isolates (three from Guinea, six from Senegal and two from 
Mali) following all the procedures described below. Approval of the study was granted by the Ethics Committee of 
the London School of Hygiene and Tropical Medicine, the National Ethics Committee for Health Research in the 
Republic of Guinea, the Ethics Committee of the Ministry of Health in Senegal, and the Ethics Committee of the 
Ministry of Health in Mali. Under approval of the Ethical Committees, all methods were performed in accordance 
with the relevant guidelines and regulations of the participating research institutes.
Parasite culture and multiplication rate assays. Parasites were cultured at 37 °C in anonymous 
adult donor erythrocytes at 3% haematocrit in RPMI 1640 medium supplemented with 0.5% Albumax II (Life 
Technologies, Paisley, United Kingdom), or in particular assays with 0.3% Albumax II and 2% human AB serum 
(GE Healthcare, Amersham, United Kingdom), under an atmosphere of 5% O2, 5% CO2, and 90% N2. Multiplication 
rate assays were conducted with up to six biological replicates, using parallel culture flasks with each flask containing 
10 mL culture using erythrocytes from a different anonymous adult donor of unknown blood group. Blood from 
multiple different donors, all adult volunteers living in the UK and working at LSHTM, was collected the day prior 
to the start of each multiplication rate assay, and erythrocytes were washed in RPMI 1640 incomplete medium and 
stored at 4 °C at 50% haematocrit. Parasite cultures were asynchronous prior to starting the assay, and each replicate 
was initiated at a parasitaemia of 0.02% by dilution of an initial culture of at least 0.2% parasitaemia into fresh donor 
erythrocytes (dilutions were a minimum of 10 fold so that at least 90% of erythrocytes within each replicate of the 
assay were from different anonymous donors). During the 6-day assay, every 48 hours (day 0, 2, 4, and 6) a 300 µL 
sample of resuspended culture medium was taken, from which 100 μL was pelleted and used to make a slide for 
giemsa staining and microscopy, with the remaining 200 μL frozen at −20 °C for DNA extraction and qPCR. Fresh 
complete RPMI medium change was performed on days 2, 4, and 5. Of the eleven clinical isolates for which high 
quality assay data were obtained for analysis, six isolates (SEN232, GUI246, MAL247, GUI249, MAL250, SEN251) 
were grown and assayed in RPMI medium with 0.5% Albumax II as for the laboratory adapted isolates, while the 
remaining five isolates were assayed in RPMI medium with 0.3% Albumax II and 2% human serum.
DNA from each culture was extracted using a DNA Blood Mini kit (Qiagen), eluted in 40 μL and stored at 
−20 °C. Genomic DNA standard controls were run in technical triplicates for each qPCR run, with a concentration 
range from 1 million down to 10 copies μL−1, and DNA extracted from each biological replicate at each timepoint 
was also assayed in technical triplicate and alongside negative template control samples. Primers targeting the highly 
conserved Pfs25 locus37 were used at 300 nM final concentration with SYBR select master mix (Applied Biosystems) 
in a total reaction volume of 10 μL, for qPCR assays run on a Rotor-Gene 3000 machine (Corbett Life Sciences and 
Qiagen), with cycling conditions of 50 °C for 2 minutes, 95 °C for 2 minutes, 40 cycles of 95 °C for 15 seconds and 
60 °C for 1 minute. Following each machine run, a melt curve was performed, to confirm specificity of the qPCR 
amplicons. Quality control filtering of the raw data involved removal of measurements that were ≥0.5 log genome 
copies different from other replicates for that individual clone. To ensure focus on high quality data, an isolate was 
dropped from analysis if there was more than one missing biological replicate data point at any time point, or if the 
final time point measurement did not have a mean of at least 500 genome copies measured in each replicate. This 
filtering enabled analysis of eleven (61%) of the eighteen clinical isolates for which the assay was initially attempted.
Design and validation of allele-specific qPCR assays. For allele-specific primer design, DNA 
sequences for several polymorphic candidate genes of four laboratory clones (Dd2, HB3, D10 and 3D7) were 
visualised in Jalview 2.8.138. Two previously described allele-specific quantitative PCR assays which targeted the 
msp1 gene21, 39 were suitable to provide discrimination of five out of the six different pairs of the four clones, so 
an additional allele-specific assay was designed to distinguish between the remaining pair (clones Dd2 and D10). 
This new assay targeted the msp6 gene (PF3D7_1035500), with one pair of primers specific for the Dd2 allele 
(5′-AAGAGCCAACATCGGAGGAATATC-3′ and 5′-CGGTTTTGAGTATTTGGTCTGGT-3′ giving an ampli-
con size of 116 bp) and another specific for the D10 allele (5′-ATCAATATACTGGTACATCTATATCAGGTAT-
3′ and 5′-CAGAGAAGTTGTAGTACTATTACTATGAGA-3′ giving an amplicon size of 148 bp). The same ther-
mocycling conditions, and validation of melt curves of products, were performed for each of these allele-specific 
qPCR assays as for the qPCR using the conserved primers described above. To validate allele-specific quantitation 
accuracy, mixtures of extracted parasite DNA with allelic match and mismatch were assayed in triplicate in the 
ratios 99:1, 90:10, 50:50, 10:90, 1:99.
P. falciparum clones expressing different fluorescent markers were used for microscopically counting the ratios 
of different parasites in mixtures, as validation tests for the accuracy of allele-specific qPCR assays for independ-
ent counting of different parasite genotypes in co-cultures. In addition to constitutively-expressed GFP fluores-
cent P. falciparum35, genetically modified lines were constructed to express GFP in clone Dd2 (Dd2-GFP), and 
the red fluorescent protein mKate240 in clone D10 (D10-mKate2). For counting of ratios of fluorescent parasites 
within controlled mixtures, parasite images were made on live parasites within a droplet of approximately 30% 
haematocrit culture under a coverslip on a glass microscope slide. These were subsequently imaged under the 40x 
lens of an EVOS FL Cell Imaging System, and proportions of each genotype were calculated by counting 200 para-
sites. For comparison of in vitro mixtures, ring-stage parasites were synchronised using a 5% sorbitol solution and 
allowed to develop into early stage trophozoite stages. Parasitaemia of the parent flask was calculated from a 1000 
red blood cell count to confirm the absence of multi-nucleate schizont stages and five artificial pairwise mixed 
scenarios were produced consisting of 20:1, 10:1, 1:1, 1:10 and 1:20 mixtures of the two differentially fluorescent 
laboratory clones. Microscopic counts were performed on the two parasites expressing the different fluorophores 
using the alternate EVOS Texas Red and GFP Light cubes, for distinction between red and green fluorescent 
parasites respectively. Images of these mixtures were taken and proportions of each genotype were calculated by 
counting at least 200 parasites.
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Microsatellite genotyping of ex vivo clinical isolates. For clinical isolates, DNA underwent microsat-
ellite genotyping at four highly polymorphic loci (TA1, Polyα, PfPK2 and TAA109), using a hemi-nested PCR 
protocol41, inner primers being labelled with particular fluorescent dyes as previously described42. PCR products 
were analysed by capillary electrophoresis using an ABI Genetic Analyzer 3730, with allele sizes discriminated 
using GENEMAPPER version 4.0 software, and minor alleles within an infection being scored if their peak height 
was at least 25% the size of the predominant allele.
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